UA114604C2 - Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9) - Google Patents

Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)

Info

Publication number
UA114604C2
UA114604C2 UAA201401793A UAA201401793A UA114604C2 UA 114604 C2 UA114604 C2 UA 114604C2 UA A201401793 A UAA201401793 A UA A201401793A UA A201401793 A UAA201401793 A UA A201401793A UA 114604 C2 UA114604 C2 UA 114604C2
Authority
UA
Ukraine
Prior art keywords
pcsk9
antibodies
antibody
relates
convertase
Prior art date
Application number
UAA201401793A
Other languages
English (en)
Inventor
Джуліан Дейвіс
Барретт Аллан
Райан Джеймс Дарлінг
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA114604C2 publication Critical patent/UA114604C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується антитіла або його антигензв'язувального фрагмента, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (PCSK9). Винахід також стосується фармацевтичної композиції, яка містить дане антитіло, та способу лікування гіперліпідемії або гіперхолестеринемії.
UAA201401793A 2011-09-16 2012-09-12 Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9) UA114604C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535625P 2011-09-16 2011-09-16
PCT/US2012/054737 WO2013039958A1 (en) 2011-09-16 2012-09-12 Antibodies to pcsk9 and uses thereof

Publications (1)

Publication Number Publication Date
UA114604C2 true UA114604C2 (uk) 2017-07-10

Family

ID=46881177

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201401793A UA114604C2 (uk) 2011-09-16 2012-09-12 Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)

Country Status (28)

Country Link
US (1) US8530414B2 (uk)
EP (1) EP2756003A1 (uk)
JP (1) JP6013487B2 (uk)
KR (1) KR101607783B1 (uk)
CN (1) CN103781802B (uk)
AP (1) AP2014007499A0 (uk)
AR (1) AR087715A1 (uk)
AU (1) AU2012308786B2 (uk)
BR (1) BR112014005799A2 (uk)
CA (1) CA2845706C (uk)
CL (1) CL2014000590A1 (uk)
CO (1) CO6910164A2 (uk)
CR (1) CR20140087A (uk)
DO (1) DOP2014000041A (uk)
EA (1) EA024430B1 (uk)
EC (1) ECSP14013242A (uk)
GT (1) GT201400049A (uk)
IL (1) IL231282A0 (uk)
MA (1) MA35433B1 (uk)
MX (1) MX347475B (uk)
MY (1) MY168961A (uk)
PE (1) PE20141147A1 (uk)
SG (1) SG2014014187A (uk)
TN (1) TN2014000094A1 (uk)
TW (1) TWI586687B (uk)
UA (1) UA114604C2 (uk)
WO (1) WO2013039958A1 (uk)
ZA (1) ZA201401267B (uk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
RU2603481C2 (ru) 2011-01-28 2016-11-27 Санофи Байотекнолоджи Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013039969A1 (en) 2011-09-16 2013-03-21 Regeneron Pharmaceuticals, Inc. METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en) 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3004171B1 (en) 2013-06-07 2021-10-13 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EP3013422A1 (en) * 2013-06-28 2016-05-04 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN105085684B (zh) * 2014-05-14 2020-04-17 上海亨臻实业有限公司 Pcsk9靶向重组疫苗设计及其应用
DE202015009007U1 (de) 2014-07-15 2016-08-19 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP4328245A3 (en) 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3332790A1 (en) 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
KR20240017117A (ko) 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
WO2016150444A1 (en) 2015-03-20 2016-09-29 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
EP3337828A1 (en) 2015-08-18 2018-06-27 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
MX2018007925A (es) * 2015-12-31 2018-08-29 Jiangsu Hengrui Medicine Co Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
WO2017118307A1 (zh) 2016-01-05 2017-07-13 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3515949A4 (en) * 2016-09-20 2020-10-28 Wuxi Biologics Ireland Limited. NEW ANTI-PCSK9 ANTIBODIES
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JOP20190112A1 (ar) 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108424457B (zh) * 2017-02-13 2021-06-01 成都金洛克锶生物技术有限公司 针对pcsk9抗体与检测试剂盒的制备及其用途
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Ltd peptídeo
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها
MX2021014015A (es) 2019-05-17 2022-02-21 Regeneron Pharma Metodos basados en el genoma para reducir el riesgo cardiovascular.
CN114369164A (zh) * 2020-10-15 2022-04-19 苏州君盟生物医药科技有限公司 抗pcsk9单克隆抗体的生产工艺

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1226243A2 (en) 1999-10-22 2002-07-31 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
EP1309614A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Novel secreted proteins and their uses
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008057458A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2681428A1 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2205639B1 (en) 2007-10-26 2015-12-23 Merck Sharp & Dohme Corp. Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
CA2720681C (en) 2008-04-23 2016-08-02 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2013509191A (ja) * 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ａｘ１およびａｘ１８９ｐｃｓｋ９アンタゴニストおよびバリアント
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체

Also Published As

Publication number Publication date
MA35433B1 (fr) 2014-09-01
PE20141147A1 (es) 2014-09-22
TWI586687B (zh) 2017-06-11
CO6910164A2 (es) 2014-03-31
WO2013039958A1 (en) 2013-03-21
CA2845706A1 (en) 2013-03-21
CN103781802A (zh) 2014-05-07
TN2014000094A1 (en) 2015-07-01
AU2012308786B2 (en) 2016-12-15
EP2756003A1 (en) 2014-07-23
CA2845706C (en) 2016-03-22
KR101607783B1 (ko) 2016-03-30
MY168961A (en) 2019-01-28
AR087715A1 (es) 2014-04-09
US20130071405A1 (en) 2013-03-21
IL231282A0 (en) 2014-04-30
JP2014530188A (ja) 2014-11-17
ECSP14013242A (es) 2014-07-31
EA024430B1 (ru) 2016-09-30
AU2012308786A1 (en) 2014-02-27
AP2014007499A0 (en) 2014-03-31
SG2014014187A (en) 2014-05-29
MX2014003175A (es) 2015-03-05
DOP2014000041A (es) 2014-06-30
CL2014000590A1 (es) 2014-10-17
GT201400049A (es) 2015-05-28
CN103781802B (zh) 2016-08-24
TW201323444A (zh) 2013-06-16
EA201490470A1 (ru) 2014-06-30
NZ622393A (en) 2015-11-27
US8530414B2 (en) 2013-09-10
KR20140044939A (ko) 2014-04-15
JP6013487B2 (ja) 2016-10-25
ZA201401267B (en) 2015-11-25
MX347475B (es) 2017-04-27
BR112014005799A2 (pt) 2017-03-28
CR20140087A (es) 2014-05-02

Similar Documents

Publication Publication Date Title
UA114604C2 (uk) Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)
PH12019501274A1 (en) Methods of treating or preventing cholesterol related disorders
EA201391157A1 (ru) Антагонисты pcsk9
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
PH12014501261B1 (en) Pcsk9 antagonists
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
TN2013000467A1 (en) Methods of treating or preventing cholesterol related disorders
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
MX2015016887A (es) Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9.
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
EA201270769A1 (ru) Антитела к cgrp
TR201906696T4 (tr) Pcsk9 antagoni̇stleri̇
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
UA103916C2 (en) Dkk-1 antibody
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201792328A1 (ru) Способ очистки белков
EA201990222A1 (ru) Антитела к o2 и пути их применения
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2